Abstract:Protein-ligand binding assays facilitate the understanding of biomolecular interactions. Classical equilibrium dialysis methods are often used for accurate determination of binding properties. While accurate, the long equilibration times associated with the technique (> 6 h) hinder throughput. Here, in an attempt to gather high-accuracy results while reducing total analysis time, a low pressure ultrafiltration method that relies on a simple membrane-containing syringe attachment was developed. A minimal portion (1-2%) of the solution containing the binding analytes of interest is driven through the membrane pores and collected for analysis. Specifically, the device was used to investigate the binding affinity between Zn2+ and either normal human serum albumin (nHSA) or a commercially purchased glycated human serum albumin (gHSA). Both of these ligand/protein-binding systems have implications in type 1 diabetes. The device was then used to investigate the binding between the various albumin types and C-peptide, the 31 amino acid peptide that is co-secreted with insulin from pancreatic β cells. Results for nHSA/Zn2+ binding obtained using the ultrafiltration method (Kd = 5.77 ± 0.19 × 10-7 M) were statistically equivalent with results reported using other methods. Importantly, the amount of Zn2+ bound to the nHSA was significantly different from the gHSA (97 ± 2% protein bound vs. 91 ± 3%, respectively p < 0.05). The binding affinity of C-peptide to nHSA (Kd = 2.4 ± 0.3 × 10-6 M) agreed with values reported in the literature using standard techniques. Unlike Zn2+ binding, the binding of C-peptide to nHSA was statistically equal to its binding to gHSA (77.7 ± 6.2 and 78.8 ± 7.4%, respectively), suggesting that C-peptide replacement therapy in people with T1D may be strongly dependent upon the characteristics of Zn2+ binding to human serum albumin. Graphical abstract ᅟ.

Studies of binding by sulfonylureas with glyoxal- and methylglyoxal-modified albumin by immunoextraction using affinity microcolumns

High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin

Generation of affinity maps for thiazolidinediones with human serum albumin using affinity microcolumns. II. Effects of advanced glycation end products on multisite drug binding

Analysis of multi-site drug-protein interactions by high-performance affinity chromatography: Binding by glimepiride to normal or glycated human serum albumin

Mechanistic physicochemical insights into glycation and drug binding by serum albumin: Implications in diabetic conditions

Inhibitory Effects of Hydroxysafflor Yellow A on the Formation of Advanced Glycation End Products in Vitro.

Understanding the effects of two bound glucose in Sudlow site I on structure and function of human serum albumin: theoretical studies

Influence of Human Serum Albumin Glycation on the Binding Affinities for Natural Flavonoids

In Vitro Spectroscopic Investigation of Losartan and Glipizide Competitive Binding to Glycated Albumin: A Comparative Study

Diabetic Glycation of Human Serum Albumin Affects Its Immunogenicity

Ultrafiltration binding analyses of glycated albumin with a 3D-printed syringe attachment

Review: Glycation of human serum albumin

Glycation and drug binding by serum albumin

Effect of different glycation agents on Cu(II) binding to human serum albumin, studied by liquid chromatography, nitrogen microwave-plasma atomic-emission spectrometry, inductively-coupled-plasma mass spectrometry, and high-resolution molecular-mass spectrometry

Influence of Glycation of Plasma Proteins in Diabetes on the Binding Interaction with Polyphenols.

Study of Hemoglobin and Human Serum Albumin Glycation with Electrochemical Techniques

Exploring glycated sites in human serum albumin: impact of sample processing techniques on detection and analysis

Glycosylation and binding of α-dicarbonyl compounds and human serum albumin based on spectral analysis and molecular simulation

Non-enzymatic glycation of human serum albumin modulates its binding efficacy towards bioactive flavonoid chrysin: A detailed study using multi-spectroscopic and computational methods

The Interaction of Human Serum Albumin with A Novel Antidiabetic Agent - Su-118

Antibodies against Gluco-Oxidatively Modified Human Serum Albumin Detected in Diabetes-Associated Complications